Invivyd, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.51
- 52-Week Range
- $0.46 – $3.01
- Market Cap
- $139.09M
- P/E (TTM)
- —
- EPS (TTM)
- -0.38
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.92
- PEG Ratio
- —
- Return on Equity
- -107.03%
- Return on Assets
- -52.70%
- Gross Margin
- 92.60%
- Operating Margin
- -224.42%
- Profit Margin
- -214.77%
- Current Ratio
- 5.51
- Debt/Equity
- 0.05
- Total Debt
- $8.25M
- Free Cash Flow
- $-88.70M
- Revenue Growth
- 17.70%
- Earnings Growth
- —
- Enterprise Value
- $20.94M
Market Snapshot
About
Invivyd, Inc. is a biopharmaceutical company dedicated to protecting vulnerable populations from serious viral infectious diseases. The company focuses on developing antibody-based therapies for infectious diseases, with an initial emphasis on COVID-19 and influenza. Invivyd's platform combines expertise in antibody discovery, engineering, and clinical development to create potent and durable antiviral therapies. The company was spun out from AstraZeneca's long-acting antibody program and continues to advance next-generation antibody treatments designed to address evolving viral threats.